Robotic Precision: ForSight's JASPER Platform Masters Cataract Surgery

CAESAREA, Israel – August 06, 2026 – In the quiet, high-stakes world of ophthalmic microsurgery, a significant threshold has been crossed. ForSight Robotics, an Israeli pioneer in robotic surgery, has announced that its JASPER™ Robotic Surgical Platform has not only performed fully robotic-assisted cataract surgeries but has done so within the standard clinical workflow of the world's most common surgical procedure.

Building on a historic first-in-human achievement earlier this year, the company has now completed a total of 26 procedures, all of which were executed robotically from start to finish without any need for manual intervention. This milestone moves the concept of robotic eye surgery from the realm of possibility to the edge of practicality, signaling a potential paradigm shift in a field that affects tens of millions of patients annually.

"Our first clinical milestone established that fully robotic-assisted cataract surgery was possible," said Joseph Nathan, MD, MSc, co-founder and Chief Executive Officer of ForSight Robotics. "This latest clinical experience demonstrates something even more important: that robotic cataract surgery can integrate naturally into the way cataract surgery is performed every day. This represents a defining milestone, not only for ForSight Robotics, but for the future of ophthalmic surgery."

A New Standard of Precision in a Routine Procedure

Cataract surgery, performed over 30 million times each year, is a marvel of modern medicine, yet it still relies entirely on the steady hands and expert judgment of a human surgeon. ForSight Robotics aims to augment that expertise with the infallible precision of a machine. The recent series of 26 surgeries underscores this potential. All patients underwent the procedure with standard anesthesia protocols and were discharged the same day, mirroring the typical outpatient experience.

The key innovation lies in the platform’s seamless integration. "One of the most encouraging aspects of this clinical experience has been how seamlessly the robotic platform fits into routine cataract surgery," noted Dr. Robert T. Ang, the study's Principal Investigator. "The robotic platform complemented, rather than disrupted, the normal clinical workflow while providing exceptional precision, stability, and control."

This level of control is achieved through a suite of advanced technologies. The JASPER™ platform uses bimanual robotic manipulators that provide surgeons with intuitive telemanipulation. This is coupled with high-definition 3D visualization, giving the operator an immersive view of the eye's delicate structures. Critically, the system incorporates real-time eye tracking to compensate for involuntary patient movements, while motion scaling and tremor elimination technologies translate the surgeon's hand movements into impossibly steady, micron-level actions. To put this in perspective, the natural tremor of a surgeon's hand averages around 180 microns, nearly the thickness of the retina itself. JASPER™ effectively erases this tremor, introducing a level of mechanical stability that is physically impossible for a human to achieve.

The Competitive Race to Automate Vision

ForSight Robotics is not operating in a vacuum. The global surgical robotics market, valued at over $7 billion in 2022 and projected to exceed $24 billion by 2032, is a fiercely competitive arena. While giants like Intuitive Surgical have long dominated fields like urology and general surgery, the niche of ophthalmology is an emerging battleground for a new wave of innovators.

Competitors like the Netherlands-based Preceyes and France's AcuSurgical have made strides, primarily focusing on complex vitreoretinal procedures. Other players, such as Horizon Surgical Systems, are also targeting the cataract space. However, ForSight’s strategic focus on mastering the complete cataract procedure—the highest volume surgery in the world—sets it apart. By targeting the most common procedure, the company is making a calculated bet on scalability and market penetration.

This ambitious goal is backed by significant capital. The company's recent funding rounds, including a substantial Series B infusion, have armed it with the resources necessary to navigate the arduous and expensive path toward regulatory approval from bodies like the FDA. This financial runway is critical, as the JASPER™ platform, while clinically promising, remains under development and is not yet commercially available. The recent clinical success is a crucial piece of evidence in the lengthy process of proving safety and efficacy to regulators, investors, and the medical community.

The Platform for an AI-Powered Future

Perhaps the most profound implication of ForSight's achievement extends beyond the ophthalmology clinic. CEO Joseph Nathan is explicit about this broader vision: "We believe robotic platforms will become the foundation for the next generation of intelligent surgery." This positions the JASPER™ platform not merely as a tool, but as a physical agent for artificial intelligence in the operating room.

The technology that enables today's precision—advanced computer vision, data collection from every movement, and real-time environmental sensing—is the very same technology that will train the surgical AI of tomorrow. In the future, such platforms could evolve to automate repetitive surgical sub-tasks, provide real-time guidance to surgeons by flagging anatomical risks, or even adapt their technique based on learnings from thousands of previous procedures. This creates a virtuous cycle where each surgery performed generates data that makes the system smarter, safer, and more efficient.

This forward-looking strategy reframes the current milestone. The successful integration into standard clinical workflows is not just about proving a robot can perform cataract surgery; it's about establishing the beachhead from which AI can begin to augment and eventually transform surgical practice across all disciplines. It is the first step in building a platform that learns.

Democratizing Sight on a Global Scale?

The ultimate promise of this technology may lie in its potential to address one of the world's most pressing public health crises. Cataracts are the leading cause of blindness globally, with an estimated 94 million people affected. A staggering 89% of visually impaired individuals live in low- and middle-income countries, where access to a qualified ophthalmic surgeon is often a luxury.

In theory, robotics could be a powerful democratizing force. By standardizing the surgical procedure and providing a platform that reduces the impact of hand tremor and enhances precision, systems like JASPER™ could potentially shorten the learning curve for surgeons and enable more consistent, high-quality outcomes across different experience levels. This could expand the pool of capable surgeons and increase throughput, helping to tackle the immense backlog of untreated cases worldwide.

However, the path to global health equity is fraught with obstacles. The high acquisition and maintenance costs of sophisticated robotic systems present a formidable barrier for healthcare systems in resource-limited settings. These platforms also demand robust infrastructure, including reliable power and technical support, which cannot be taken for granted. While ForSight Robotics has stated a mission to "democratize quality surgical eye care globally," the economic realities of deploying this technology on a global scale remain a significant challenge. The true test will be whether the company can develop a business model that makes this revolutionary precision accessible not just to the few, but to the millions who desperately need it.